Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy.
Although mitogen-activated protein kinase (MAPK) inhibitors elicit initial regression of BRAF-mutated melanoma, drug resistance is an inevitable and fatal event. We recently reported that in genetically engineered mouse models of BRAF-mutated melanoma, isoform-selective phosphatidylinositol 3-kinase inhibition cooperates with MAPK pathway inhibition to forestall the onset of MAPK pathway inhibitor resistance.
Helen Diller Family Comprehensive Cancer Center and Department of Cell and Molecular Pharmacology, University of California , San Francisco, CA, USA.
Marian M
MM
Deuker
Helen Diller Family Comprehensive Cancer Center and Department of Cell and Molecular Pharmacology, University of California , San Francisco, CA, USA.
Martin
M
McMahon
Mechanisms of oncogenesis and tumor progression; mechanisms of resistance to therapy; novel therapeutic agents; novel therapeutic targets